Evidence map›Paper›PMID 26109723›Full record

ArticleJournal of virology2015

A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP.

Crystal Woodard, Gangling Liao, C Rory Goodwin, Jianfei Hu, Zhi Xie, Thaila F Dos Reis, Rob Newman, Heesool Rho, Jiang Qian, Heng Zhu and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  7. Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime upon ovarian cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Crystal WoodardHigh Throughput Biology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Department of Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Gangling LiaoDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
C Rory GoodwinHigh Throughput Biology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jianfei HuHigh Throughput Biology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Zhi XieDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Thaila F Dos ReisHigh Throughput Biology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rob NewmanHigh Throughput Biology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Heesool RhoHigh Throughput Biology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jiang QianDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Heng ZhuHigh Throughput Biology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Department of Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA hzhu4@jhmi.edu dhayward@jhmi.edu.
S Diane HaywardDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA hzhu4@jhmi.edu dhayward@jhmi.edu.
Johns Hopkins Medicine · USHigh Throughput Biology (United States) · USJohns Hopkins University · US

Funding

DNA-Binding Activity of Human Transcription FactorsR01GM076102 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ZHU, HENG · 2006 to 2014
$2.6M
Targeting Kinases that Phosphorylate the KSHV LANA Chromatin Binding DomainR21CA171814 · NCI · JOHNS HOPKINS UNIVERSITY · PI HAYWARD, S DIANE · 2012 to 2013
$377k
NCI NIH HHS R21 CA171814NCI NIH HHS R21CA171814NIGMS NIH HHS R01 GM076102NIGMS NIH HHS R01GM076102
6 · The paper itself

Abstract

unlabelledThe Kaposi's sarcoma-associated herpesvirus (KSHV) LANA protein is essential for the replication and maintenance of virus genomes in latently KSHV-infected cells. LANA also drives dysregulated cell growth through a multiplicity of mechanisms that include altering the activity of the cellular kinases extracellular signal-regulated kinase (ERK) and glycogen synthase kinase 3 (GSK-3). To investigate the potential impact of these changes in enzyme activity, we used protein microarrays to identify cell proteins that were phosphorylated by the combination of ERK and GSK-3. The assays identified 58 potential ERK-primed GSK-3 substrates, of which 23 had evidence for in vivo phosphorylation in mass spectrometry databases. Two of these, SMAD4 and iASPP, were selected for further analysis and were confirmed as ERK-primed GSK-3 substrates. Cotransfection experiments revealed that iASPP, but not SMAD4, was targeted for degradation in the presence of GSK-3. iASPP interferes with apoptosis induced by p53 family members. To determine the importance of iASPP to KSHV-infected-cell growth, primary effusion lymphoma (PEL) cells were treated with an iASPP inhibitor in the presence or absence of the MDM2 inhibitor Nutlin-3. Drug inhibition of iASPP activity induced apoptosis in BC3 and BCBL1 PEL cells but did not induce poly(ADP-ribose) polymerase (PARP) cleavage in virus-negative BJAB cells. The effect of iASPP inhibition was additive with that of Nutlin-3. Interfering with iASPP function is therefore another mechanism that can sensitize KSHV-positive PEL cells to cell death. IMPORTANCE: KSHV is associated with several malignancies, including primary effusion lymphoma (PEL). The KSHV-encoded LANA protein is multifunctional and promotes both cell growth and resistance to cell death. LANA is known to activate ERK and limit the activity of another kinase, GSK-3. To discover ways in which LANA manipulation of these two kinases might impact PEL cell survival, we screened a human protein microarray for ERK-primed GSK-3 substrates. One of the proteins identified, iASPP, showed reduced levels in the presence of GSK-3. Further, blocking iASPP activity increased cell death, particularly in p53 wild-type BC3 PEL cells.

Indexed as

Antigens, ViralApoptosisCells, CulturedDrug Evaluation, PreclinicalEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesGlycogen Synthase Kinase 3Herpesvirus 8, HumanHumansImidazolesIntracellular Signaling Peptides and ProteinsNuclear ProteinsPiperazinesRepressor ProteinsSmad4 ProteinTumor Suppressor Protein p53Antigens, ViralEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesGlycogen Synthase Kinase 3ImidazolesIntracellular Signaling Peptides and Proteinslatency-associated nuclear antigenNuclear Proteinsnutlin 3PiperazinesPPP1R13L protein, humanRepressor ProteinsSmad4 ProteinSMAD4 protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID26109723
PMCPMC4542386
OpenAlexW1772394351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.